258 related articles for article (PubMed ID: 27806283)
1. Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes.
Sartiani L; Bucciantini M; Spinelli V; Leri M; Natalello A; Nosi D; Maria Doglia S; Relini A; Penco A; Giorgetti S; Gerace E; Mannaioni G; Bellotti V; Rigacci S; Cerbai E; Stefani M
Biophys J; 2016 Nov; 111(9):2024-2038. PubMed ID: 27806283
[TBL] [Abstract][Full Text] [Related]
2. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Zhao L; Buxbaum JN; Reixach N
Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
[TBL] [Abstract][Full Text] [Related]
3. A FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes.
Ami D; Mereghetti P; Leri M; Giorgetti S; Natalello A; Doglia SM; Stefani M; Bucciantini M
Sci Rep; 2018 Aug; 8(1):12508. PubMed ID: 30131519
[TBL] [Abstract][Full Text] [Related]
4. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
[TBL] [Abstract][Full Text] [Related]
6. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
7. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
[TBL] [Abstract][Full Text] [Related]
8. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
9. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
Palaninathan SK
Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
[TBL] [Abstract][Full Text] [Related]
10. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
11. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
Zhang Q; Kelly JW
Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
[TBL] [Abstract][Full Text] [Related]
12. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
13. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation.
Ferreira N; Saraiva MJ; Almeida MR
FEBS Lett; 2011 Aug; 585(15):2424-30. PubMed ID: 21740906
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of transthyretin aggregation and toxicity.
Gasperini RJ; Klaver DW; Hou X; Aguilar MI; Small DH
Subcell Biochem; 2012; 65():211-24. PubMed ID: 23225005
[TBL] [Abstract][Full Text] [Related]
15. Cooperative stabilization of transthyretin by clusterin and diflunisal.
Greene MJ; Klimtchuk ES; Seldin DC; Berk JL; Connors LH
Biochemistry; 2015 Jan; 54(2):268-78. PubMed ID: 25478940
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
17. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Green NS; Foss TR; Kelly JW
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
[TBL] [Abstract][Full Text] [Related]
19. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.
Gustavsson A; Jahr H; Tobiassen R; Jacobson DR; Sletten K; Westermark P
Lab Invest; 1995 Nov; 73(5):703-8. PubMed ID: 7474944
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]